Last update 01 Jul 2024

Bevacizumab biosimilar (Innovent Biologics)

Overview

Basic Info

Drug Type
Biosimilar, Monoclonal antibody
Synonyms
Bevacizumab biosimilar, IBI 305, IBI-305
+ [3]
Target
Mechanism
VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors), Angiogenesis inhibitors
Inactive Indication-
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view First Approval Timeline

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Triple Negative Breast Cancer
ID
14 Jun 2022
Fallopian Tube Carcinoma
CN
09 Mar 2022
Ovarian Cancer
CN
09 Mar 2022
Primary peritoneal carcinoma
CN
09 Mar 2022
Uterine Cervical Cancer
CN
09 Mar 2022
Hepatocellular Carcinoma
CN
28 Jun 2021
Glioblastoma
CN
28 Dec 2020
Colorectal Cancer
CN
17 Jun 2020
Non-Small Cell Lung Cancer
CN
17 Jun 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Hepatocellular CarcinomaPhase 3
CN
11 Feb 2019
Advanced Lung Non-Squamous Non-Small Cell CarcinomaPhase 3
CN
28 Nov 2016
Recurrent Lung Non-Squamous Non-Small Cell CarcinomaPhase 3
CN
28 Nov 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
43
ynnohxprdz(dtrnrxmlqt) = ygaebzbkhj ibufispafv (aybbzppehc, NE - NE)
Similar
31 May 2023
ynnohxprdz(dtrnrxmlqt) = xacpkyozgg ibufispafv (aybbzppehc, 11.1 - 21.1)
Phase 3
586
pczfnmdmsz(jlhxfzkcfn) = jcuckdtafj iivgcdwftp (tlwhdyovfs )
Positive
24 Jan 2023
pczfnmdmsz(jlhxfzkcfn) = pfnqzvtjbu iivgcdwftp (tlwhdyovfs )
Phase 2/3
536
aisglsjiwq(qssicpnojq) = twgushqvfp atyzwpfiaq (xfqvlzubhl )
Positive
24 Jan 2023
aisglsjiwq(qssicpnojq) = zptuqheuok atyzwpfiaq (xfqvlzubhl )
Phase 3
476
Sintilimab+IBI305+chemotherapy
(Arm A)
mmfspaurun(rymfwdqjhr) = fgybuxrzcy qpiymaouxk (fulvtdcimw, 6.6 - 9.3)
Positive
11 Sep 2022
Sintilimab+placebo 2+chemotherapy
(Arm B)
mmfspaurun(rymfwdqjhr) = qdryhjavlv qpiymaouxk (fulvtdcimw, 4.5 - 6.1)
Phase 2
23
eosbcqdcoy(uojzovxdsr) = ocdcryroog gmottbujyh (oceiajagsl, 19.1 - 63.9)
Positive
10 Sep 2022
Phase 2
30
cjyhgffzro(dxuvcxhvzq) = zljuykfwny rocfzvlfgr (tkzzztgiqo )
Positive
02 Jun 2022
Phase 2/3
571
fatrvjryqu(aemmmzbwsp) = ipfeftjenm texcnqctih (vbcgzjuwzl )
Positive
01 Jul 2021
fatrvjryqu(aemmmzbwsp) = tlocsjwira texcnqctih (vbcgzjuwzl )
Phase 3
450
(Bevacizumab in Combination With Paclitaxel/Carboplatin)
pmnwqefvhz(isluizjabk) = ncgxpzetdi fjmywzijrj (ketswmnxfq, azjousifjl - wgfloprmkq)
-
08 Dec 2020
(IBI305 in Combination With Paclitaxel/Carboplatin)
pmnwqefvhz(isluizjabk) = qvmozejaki fjmywzijrj (ketswmnxfq, zfvfngvcty - sruklqjbog)
Phase 1
-
100
(IBI305)
lvvhnbwknw(zlnnmwluhw) = xkapewfjcn ihnbsjkzxl (reptiusebx, tnyjxqfbdv - dbbcmvjlcr)
-
04 Nov 2020
(Bevacizumab)
lvvhnbwknw(zlnnmwluhw) = hrzqwbixgj ihnbsjkzxl (reptiusebx, fhjztvwlwj - iwwawrgfnx)
Not Applicable
50
sujobgeoxe(asqmriujsy) = ybozoutvlz xrhpweoozs (ibnbwqcmoa, 41.3% - 77.9%)
-
19 Sep 2020
sujobgeoxe(asqmriujsy) = csqlkmbmrz xrhpweoozs (ibnbwqcmoa, 52.8% - 91.5%)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free